摘要 |
The present invention relates to a method for diagnosing pancreatic cancer in a subject comprising the steps of: (a) determining in at least one sample of said subject the amounts of a group of diagnostic biomarkers comprising (i) at least one diagnostic amino acid, said diagnostic amino acid being proline, histidine or tryptophan, preferably, being proline; (ii) at least one diagnostic ceramide, said diagnostic ceramide being ceramide (d18:1,C24:0) or ceramide (d18:2,C24:0), preferably being ceramide (d18:1,C24:0); (iii) at least one diagnostic sphingomyelin, said diagnostic sphingomyelin being sphingomyelin (35:1), sphingomyelin (d17:1,C16:0), sphingomyelin (41 :2) or sphingomyelin (d18:2,C17:0), preferably being sphingomyelin (35:1); and (iv) CA19-9; and (b) comparing said amounts of the diagnostic biomarkers with a reference, whereby pancreatic cancer is diagnosed. Moreover, the present invention relates to a method for determining the probability for a subject to suffer from pancreatic cancer, and to devices and uses related to said methods. |
申请人 |
METANOMICS HEALTH GMBH |
发明人 |
KAMLAGE, Beate;RESZKA, Regina;SCHATZ, Philipp;DOSTLER, Martin;CARVALHO, Susan;PETER, Erik;MAPPES, Philipp;KALTHOFF, Holger;SCHNIEWIND, Bodo;MAYERLE, Julia;LERCH, Markus;GRUETZMANN, Robert;PILARSKY, Christian |